Program
atebimetinib
Also written as “Atebimetinib”, “IMM-1-104 Monotherapy (Treatment Group A)” and “IMM-1-104 + modified FOLFIRINOX (Treatment Group C)”.
Its studies are mostly in Pancreatic Neoplasms · Melanoma, Cutaneous Malignant, led by Immuneering.
Furthest: phase 3, since Apr 20, 20262 company-led studies, 2 open or runningNext primary completion: Jun 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Immuneering | 22 open or running | phase 3since Apr 20, 2026 | Oct 14, 2022 | Jun 2027phase 2 · NCT05585320 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 14, 2022First study: phase 2 study in Melanoma, Cutaneous MalignantFirst studyNCT05585320 · 209 enrolled · United States
- Apr 20, 2026Phase 3 study in Pancreatic NeoplasmsPhase 3 reachedNCT07562152 · 570 planned · United States, Australia, Georgia and more
Ahead
- Jun 2027Primary completion: phase 2 study in Melanoma, Cutaneous MalignantNCT05585320
- Jun 2028Primary completion: phase 3 study in Pancreatic NeoplasmsNCT07562152
TargetBeta
MAP2K2 →read by rule
“An orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPK/ERK kinase; MEK) 1 and MEK2, ”NCIt, by rule
Other programs on MAP2K2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| cobimetinibrule | Hoffmann-La Roche | phase 3 | 38 |
| pimasertibrule | Merck KGaA, Darmstadt, Germany | phase 2 | 13 |
| mirdametinibrule | Merck KGaA, Darmstadt, Germany | phase 2 | 9 |
| polfurmetinib | Pfizer | phase 1 | 3 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07562152Pancreatic Neoplasms · United States, Australia, Georgia and more | 3 | Recruiting | Jun 2028 | 570 |
| NCT05585320Melanoma, Cutaneous Malignant · United States | 2 | Active, not recruiting | Jun 2027 | 209 |
How it is read
Names in the registry
- “Atebimetinib”, 1 entry
- “IMM-1-104 Monotherapy (Treatment Group A)”, 1 entry
- “IMM-1-104 + modified FOLFIRINOX (Treatment Group C)”, 1 entry
- “IMM-1-104 + dabrafenib (Treatment Group D)”, 1 entry
- “IMM-1-104 + pembrolizumab (Treatment Group E)”, 1 entry
Conditions, from the studies’ own filings
- Pancreatic Neoplasms, 1 study
- Melanoma, Cutaneous Malignant, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.